This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Germany continues to spearhead the move higher for the rest of the eurozone having broken through the 12,000 level less than a month after moving above 11,000.
As cheerful as the average German might be about the DAX this propensity for optimism does not stretch towards the Greeks. The last month has seen the percentage of Germans wanting Greece to exit the eurozone increase from 41% up to 52%.
The grumblings of discontent between German and Greek ministers has once more escalated as the focus on historical wrongdoings has led to even more bitter sentiment, and the phrase ‘don’t bite the hand that feeds you’ appears to not translate well into Greek.
BP’s risk appetite looks to have returned with the news that it has agreed a new $12 billion investment in Egypt aimed at increasing the company’s production by three billion barrels.
Sainsbury’s sits atop of the list of FTSE fallers just twenty-four hours before publishing its fourth-quarter figures, offering a glimpse of what the market is expecting.
AstraZeneca shares have struggled this morning following the news that its Brilinta heart drug trials have proven to be less successful than hoped.
The dollar remains the primary focus of the currency markets as anticipation of Wednesday’s Federal Open Market Committee statement reaches fever pitch. Markets appear to be factoring in a change of phraseology from the Fed as expectations of a US rate change have moved as close as June judging by comments from some institutions.
It is not often that US markets have played second fiddle to their European counterparts, but the driving force of the European quantitative easing scheme continues to see them set the pace as US equity indices struggle to keep up.
Ahead of the open we expect the Dow Jones to start 47 points higher at 17,796.